DSPE-PEG2000-RVG29

Cat. No.: HY-172705: Data Sheet
SDS
Handling Instructions
FAQs
Technical Support

DSPE-PEG2000-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG2000-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG2000-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions.

For research use only. We do not sell to patients.

DSPE-PEG2000-RVG29 Chemical Structure

Size	Stock	Quantity
5 mg	Get quote 7 - 9 Weeks 6 - 8 Weeks 8 - 10 Weeks 7 - 9 weeks	Estimated Time of Arrival: December 31
10 mg	Get quote 7 - 9 Weeks 6 - 8 Weeks 8 - 10 Weeks 7 - 9 weeks	Estimated Time of Arrival: December 31
25 mg	Get quote 7 - 9 Weeks 6 - 8 Weeks 8 - 10 Weeks 7 - 9 weeks	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE DSPE-PEG2000-RVG29

•J Nanobiotechnology. 2025 Nov 3;23(1):696. [Abstract]

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	DSPE-PEG2000-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG2000-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG2000-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions^[2].
In Vitro	DSPE-PEG2000-RVG29-containing M-R@siC-NPs exhibit uniform size distribution, near-neutral surface charge, efficient siRNA loading, and long-term structural stability in biological media^[1]. DSPE-PEG2000-RVG29-containing M-R@siC-NPs (20-120 μg/mL; 24 h) show low cytotoxicity in primary astrocytes at concentrations up to 80 μg/mL, with reduced viability at higher doses^[1]. DSPE-PEG2000-RVG29-functionalized BAELPP (0.5 μg DNA equivalent per well; 24 h/48 h) achieves high transfection efficiency in SH-SY5Y human neuroblastoma cells with low cytotoxicity^[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. DSPE-PEG2000-RVG29 Related Antibodies
In Vivo	M-R@siC-NPs (containing DSPE-PEG2000-RVG29) (80 μg/mL; intraperitoneal) effectively suppress hippocampal astrocyte activation, reduce neuroinflammation, and improve motor coordination and spatial memory in HIBD neonatal mice^[1]. DSPE-PEG2000-RVG29 (10 mol%; retro-orbital injection) modification enhances brain targeting of lipopolyplexes, resulting in increased and localized transgene expression in the mouse striatum and substantia nigra^[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight	2000 (Average)
SMILES	[Mal-Cys-YTIWMPENPRPGTPCDIFTNSRGKRASNG]C(CCOCCOC(NCCOP(OC[C@](COC(CCCCCCCCCCCCCCCCC)=O)([H])OC(CCCCCCCCCCCCCCCCC)=O)(O)=O)=O)=O.[n]
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (273 KB) SDS (252 KB) Handling Instructions (2659 KB)
References	[1]. Dang Y, et al. Dual-Modified Mannose/RVG29 Peptide-Functionalized Lipid Nanoparticles Loaded With circHIPK2 siRNA Ameliorate Hypoxic-Ischemic Brain Damage in Neonatal Mice by Suppressing Astrocyte Activation. J Integr Neurosci. 2025;24(12):45212. [Content Brief] [2]. Yujing Zhang, et al. Advancing Parkinson's Prevention: Brain-Specific Lipopolyplex Delivery of Gdnf as a Neuroprotective Gene Therapy. 40 Pages Posted: 8 Jul 2025.